Cagri-TRZ Blend -11mg

Cagri-TRZ is a dual peptide blend in a single lyophilized formulation pairing a long acting amylin analogue with a dual GIP/GLP-1 incretin receptor agonist to produce a compound blend targeting three distinct metabolic receptor pathways simultaneously. iLab Pharma’s formulation supplies 11mg total across both peptide components as a lyophilized vial, preserving structural integrity and potency of both compounds across storage conditions until reconstitution.

The rationale behind this specific combination is grounded in the complementary and non overlapping mechanisms of the two components. Trz dual GIP and GLP-1 receptor agonism drives glucose dependent insulin secretion, glucagon suppression, gastric emptying delay, and central nervous system satiety signaling through incretin pathways. Cagri is a long acting analogue of amylin. A peptide co secreted with insulin by pancreatic beta cells which operates through amylin receptor activation to produce complementary satiety signaling, gastric emptying regulation, and glucagon suppression through a completely separate receptor system from GLP-1 and GIP. The combination of incretin and amylin pathway co activation produces a mechanistically distinct research profile from either compound alone or from triple incretin agonists like GLP-3 RTA, making Cagri-TRZ a uniquely positioned compound in the metabolic research landscape.

Cagri amylin analogue characteristics are worth specific attention for research context. Native amylin has a short half life and limited research utility as a standalone compound. Cagri long acting structural modifications address this limitation, providing sustained amylin receptor activation suited to extended research protocols. The pairing with Trz incretin activity creates a formulation where all three receptor systems. GLP-1, GIP, and amylin are simultaneously engaged, a mechanistic combination that has generated significant research interest in studies examining synergistic appetite regulation and metabolic pathway co activation beyond the incretin axis alone.

iLab Pharma formulations are stocked by Canada Steroid Depot following the same rigorous third party lab verification process applied to every product in our range. Each batch is tested for concentration accuracy and purity across both peptide components before being made available, with COA documentation available on request. CSD’s incretin and metabolic peptide range covers single, dual, and triple receptor pathway options alongside this unique incretin amylin combination, giving researchers access to the most comprehensive metabolic peptide sourcing available from a single verified Canadian supplier. All orders ship discreetly across Canada in plain, unmarked packaging with no identifying information on the exterior.

Reconstitute with bacteriostatic water prior to use. Store lyophilized peptide at 2–8°C away from direct light. Once reconstituted refrigerate and use within 28 days. Intended for research purposes only.

Commonly researched alongside dual and triple incretin agonist compounds in comparative metabolic receptor pathway studies. Browse CSD’s full peptide range for complete sourcing.